Sinopharm Group CoSHTDY +2.87%73 ROC (Joel Greenblatt) % is 13.81% as of Dec. 2025, which is 51% below its 10-year median of 28.05. GuruFocus rates SHTDY with a GF Score™ of 73/100 and a GF Value™ of $13.05 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 118 Medical Distribution companies, Sinopharm Group Co ranks worse than 54.24% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Sinopharm Group Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 13.81%.
The historical rank and industry rank for Sinopharm Group Co's ROC (Joel Greenblatt) % or its related term are showing as below:
SHTDY'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 14.31 Med: 28.05 Max: 47
Current: 14.31
During the past 13 years, Sinopharm Group Co's highest ROC (Joel Greenblatt) % was 47.00%. The lowest was 14.31%. And the median was 28.05%.
SHTDY's ROC (Joel Greenblatt) % is ranked worse than 54.24% of 118
companies
in the Medical Distribution industry
Industry Median: 15.345
vs SHTDY: 14.31
Sinopharm Group Co's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was -11.50% per year.
Sinopharm Group Co (OTCPK:SHTDY) ROC (Joel Greenblatt) % Explanation
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
Sinopharm Group Co ROC (Joel Greenblatt) % Related Terms
Sinopharm Group Co ROC (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Sinopharm Group Co's ROC (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHTDY vs MCK, CAH, COR: ROC (Joel Greenblatt) % Comparison
For the Medical Distribution subindustry, Sinopharm Group Co's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sinopharm Group Co ROC (Joel Greenblatt) % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Sinopharm Group Co's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Sinopharm Group Co's ROC (Joel Greenblatt) % falls into.
Sinopharm Group Co ROC (Joel Greenblatt) % Calculation
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of 13.81% mean?
Sinopharm Group Co (SHTDY) has a ROC (Joel Greenblatt) % of 13.81% as of Dec. 2025. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Sinopharm Group Co and its competitors. This is 51% below median its historical median of 28.05. Over the past decade, Sinopharm Group Co's ROC (Joel Greenblatt) % has ranged from 14.31 to 47.00. According to the industry distribution chart, Sinopharm Group Co ranks #64 out of 118 companies in the Medical Distribution industry, placing it in the top 54.2%.
Is Sinopharm Group Co's ROC (Joel Greenblatt) % too high?
Sinopharm Group Co's current ROC (Joel Greenblatt) % of 13.81% is 51% below median its 10-year median of 28.05. Over the past 10 years, this metric has ranged from a low of 14.31 to a high of 47.00. The Medical Distribution industry median ROC (Joel Greenblatt) % is 15.35. Sinopharm Group Co's value of 13.81% is 10% below this industry median. Based on the distribution chart, Sinopharm Group Co ranks #64 out of 118 companies in the Medical Distribution industry, which is below the industry midpoint. Overall, Sinopharm Group Co has a GF Score™ of 73/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sinopharm Group Co's ROC (Joel Greenblatt) % compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Sinopharm Group Co ranks #64 out of 118 companies for ROC (Joel Greenblatt) %. This places Sinopharm Group Co in the lower half of its industry. The industry median ROC (Joel Greenblatt) % is 15.35. Sinopharm Group Co's value of 13.81% is 10% below this benchmark. Historically, Sinopharm Group Co's own ROC (Joel Greenblatt) % has ranged from 14.31 to 47.00 over the past decade. While the company's 10-year median is 28.05 vs. the industry median of 15.35, Sinopharm Group Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Medical Distribution company?
The median ROC (Joel Greenblatt) % among Medical Distribution companies is 15.35, based on 118 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sinopharm Group Co's current ROC (Joel Greenblatt) % of 13.81% is 10% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Sinopharm Group Co and its competitors. For the Medical Distribution industry, the median ROC (Joel Greenblatt) % is 15.35 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sinopharm Group Co's current ROC (Joel Greenblatt) % is 13.81%, which is 51% below median its own 10-year median of 28.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sinopharm Group Co stock overvalued right now?
Based on GuruFocus' analysis, Sinopharm Group Co (SHTDY) is currently considered Modestly Undervalued. The stock's GF Value™ is $13.05, compared to a current price of $10.45 — trading 19.9% below its estimated fair value. The current ROC (Joel Greenblatt) % is 13.81%, which is 51% below median its 10-year median of 28.05 and 10% below the Medical Distribution industry median of 15.35. Sinopharm Group Co's overall GF Score™ is 73/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Sinopharm Group Co (SHTDY), the current ROC (Joel Greenblatt) % is 13.81% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sinopharm Group Co (SHTDY) Overvalued in 2026?
Based on GuruFocus' analysis, Sinopharm Group Co stock appears to be undervalued.
The current stock price of $10.45 is trading 19.9% below its estimated GF Value™ of $13.05.
GuruFocus considers Sinopharm Group Co to be Modestly Undervalued.
Key valuation signals for SHTDY:
ROC (Joel Greenblatt) %: 13.81% (51% below median its 10-year median of 28.05)
GF Value™: $13.05 vs. price of $10.45 (19.9% below fair value)
Industry Position: 10% below the Medical Distribution median (#64 of 118)
No single metric tells the full story. See the SHTDY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Founded in 2003, Sinopharm is the largest wholesaler and retailer of drugs and medical devices in China and listed on the Hong Kong Stock Exchange in 2009. It is a core subsidiary of China National Pharmaceutical Group. Sinopharm's largest operating segment is pharmaceutical distribution, making up over 70% of its total revenue by the end of 2024. In 2018, Sinopharm acquired the largest Chinese medical device distributor, China National Scientific Instruments and Materials. Now, medical device distribution accounts for over 20% of Sinopharm's total revenue. Sinopharm's downstream customers range from hospitals and other health services institutions to end-customers.
73GF Score
Get the complete analysis for SHTDY
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHTDY has been successfully added to your 
